These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 25174683)
1. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex. Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683 [TBL] [Abstract][Full Text] [Related]
2. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex. Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960 [TBL] [Abstract][Full Text] [Related]
3. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update. Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771 [TBL] [Abstract][Full Text] [Related]
4. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. Wheless JW; Almoazen H J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial. Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial. Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H; JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048 [TBL] [Abstract][Full Text] [Related]
7. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771 [TBL] [Abstract][Full Text] [Related]
8. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex. Lee YI; Lee JH; Kim DY; Chung KY; Shin JU Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060 [TBL] [Abstract][Full Text] [Related]
9. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions. Tu J; Foster RS; Bint LJ; Halbert AR Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523 [TBL] [Abstract][Full Text] [Related]
10. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial. Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026 [TBL] [Abstract][Full Text] [Related]
11. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Foster RS; Bint LJ; Halbert AR Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333 [TBL] [Abstract][Full Text] [Related]
12. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis. Mutizwa MM; Berk DR; Anadkat MJ Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776 [No Abstract] [Full Text] [Related]
13. Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost. Norrenberg S; Masconi M; Karamanou M; Meylan P; Golaz R; Christen-Zaech S Br J Dermatol; 2018 Jul; 179(1):208-209. PubMed ID: 29380350 [No Abstract] [Full Text] [Related]
14. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus]. Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155 [TBL] [Abstract][Full Text] [Related]
15. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence. Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748 [TBL] [Abstract][Full Text] [Related]
16. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis. Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193 [No Abstract] [Full Text] [Related]
17. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy. Park J; Yun SK; Cho YS; Song KH; Kim HU Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865 [TBL] [Abstract][Full Text] [Related]
18. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report. Dill PE; De Bernardis G; Weber P; Lösch U Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875 [TBL] [Abstract][Full Text] [Related]
19. Targeted topical and combination laser surgery for the treatment of angiofibromas. Bae-Harboe YS; Geronemus RG Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238 [TBL] [Abstract][Full Text] [Related]
20. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Haemel AK; O'Brian AL; Teng JM Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030 [No Abstract] [Full Text] [Related] [Next] [New Search]